Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells

Abstract

Breast tumor kinase (BRK) is an intracellular tyrosine kinase expressed in differentiating epithelial cells of the gastrointestinal tract and skin, and in several epithelial cancers including carcinomas of the breast and colon. We examined expression of BRK and its mouse ortholog Src-related intestinal kinase (Sik) in prostate tissues and detected it in the nuclei of normal luminal prostate epithelial cells. BRK localization was then examined in 58 human prostate biopsy samples representing various grades of prostate cancer. While nuclear localization of BRK was present in well-differentiated tumors, it was absent in poorly differentiated tumors. However localization of Sam68, a nuclear substrate of BRK/Sik, was unaltered in all prostate tumors examined. Consistent with these results, nuclear BRK was detected in the more differentiated androgen-responsive LNCaP human prostate cancer cell line that is poorly tumorigenic in host animals, but it was primarily cytoplasmic in the undifferentiated androgen-unresponsive PC3 prostate cancer cell line that forms aggressive tumors. While PC3 cells expressed higher levels of endogenous BRK than LNCaP cells, BRK was less active in these cells. Our data suggest that BRK plays a role in differentiation of prostate epithelial cells. Altered BRK localization and/or activity may provide a prognostic indicator for prostate tumor progression and be a potential target for therapeutic intervention.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 7
Figure 6
Figure 8
Figure 9

Similar content being viewed by others

References

  • Abate-Shen C and Shen MM . (2000). Genes Dev., 14, 2410–2434.

  • Barker KT, Jackson LE and Crompton MR . (1997). Oncogene, 15, 799–805.

  • Barlat I, Maurier F, Duchesne M, Guitard E, Tocque B and Schweighoffer F . (1997). J. Biol. Chem., 272, 3129–3132.

  • Blume-Jensen P and Hunter T . (2001). Nature, 411, 355–365.

  • Chen T, Boisvert FM, Bazett-Jones DP and Richard S . (1999). Mol. Biol. Cell, 10, 3015–3033.

  • Coyle JH, Guzik BW, Bor YC, Jin L, Eisner-Smerage L, Taylor SJ, Rekosh D and Hammarskjold ML . (2003). Mol. Cell. Biol., 23, 92–103.

  • Denegri M, Chiodi I, Corioni M, Cobianchi F, Riva S and Biamonti G . (2001). Mol. Biol. Cell, 12, 3502–3514.

  • Derry JJ, Richard S, Valderrama Carvajal H, Ye X, Vasioukhin V, Cochrane AW, Chen T and Tyner AL . (2000). Mol. Cell. Biol., 20, 6114–6126.

  • Djakiew D . (2000). Prostate, 42, 150–160.

  • Easty DJ, Mitchell PJ, Patel K, Florenes VA, Spritz RA and Bennett DC . (1997). Int. J. Cancer, 71, 1061–1065.

  • Feldman BJ and Feldman D . (2001). Nature Rev. Cancer, 1, 34–45.

  • Gleason DF and Mellinger GT . (1974). J. Urol., 111, 58–64.

  • Hartmann AM, Nayler O, Schwaiger FW, Obermeier A and Stamm S . (1999). Mol. Biol. Cell, 10, 3909–3926.

  • Hellawell GO and Brewster SF . (2002). BJU Int., 89, 230–240.

  • Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK and, Sandberg AA . (1980). Prog. Clin. Biol. Res., 37, 115–132.

  • Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF and Jones LW . (1979). Invest Urol., 17, 16–23.

  • Lee ST, Strunk KM and Spritz RA . (1993). Oncogene, 8, 3403–3410.

  • Lim DJ, Liu XL, Sutkowski DM, Braun EJ, Lee C and Kozlowski JM . (1993). Prostate, 22, 109–118.

  • Llor X, Serfas MS, Bie W, Vasioukhin V, Polonskaia M, Derry J, Abbott CM and Tyner AL . (1999). Clin. Cancer Res., 5, 1767–1777.

  • Matter N, Herrlich P and Konig H . (2002). Nature, 420, 691–695.

  • Mitchell PJ, Barker KT, Martindale JE, Kamalati T, Lowe PN, Page MJ, Gusterson BA and Crompton MR . (1994). Oncogene, 9, 2383–2390.

  • Mitchell PJ, Sara EA and Crompton MR . (2000). Oncogene, 19, 4273–4282.

  • Reddy TR, Xu W, Mau JK, Goodwin CD, Suhasini M, Tang H, Frimpong K, Rose DW and Wong-Staal F . (1999). Nat. Med., 5, 635–642.

  • Resnick RJ, Taylor SJ, Lin Q and Shalloway D . (1997). Oncogene, 15, 1247–1253.

  • Siyanova EY, Serfas MS, Mazo IA and Tyner AL . (1994). Oncogene, 9, 2053–2057.

  • Soros VB, Carvajal HV, Richard S and Cochrane AW . (2001). J. Virol., 75, 8203–8215.

  • Vasioukhin V, Serfas MS, Siyanova EY, Polonskaia M, Costigan VJ, Liu B, Thomason A and Tyner AL . (1995). Oncogene, 10, 349–357.

  • Vasioukhin V and Tyner AL . (1997). Proc. Natl. Acad. Sci. USA, 94, 14477–14482.

  • Vernet C and Artzt K . (1997). Trends Genet., 13, 479–484.

Download references

Acknowledgements

This work was supported by the National Institutes of Health Grants DK44525 (ALT) and NIDDK 40890 (GSP).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Angela L Tyner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Derry, J., Prins, G., Ray, V. et al. Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene 22, 4212–4220 (2003). https://doi.org/10.1038/sj.onc.1206465

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206465

Keywords

This article is cited by

Search

Quick links